Article metrics

Download PDFPDF

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)

 

Online download statistics by month:

Online download statistics by month: January 2020 to January 2024

AbstractFullPdf
Jan 2020031
Feb 2020053
Mar 2020011
Apr 2020051
May 2020050
Jun 20200130
Jul 2020031
Aug 2020032
Sep 2020082
Oct 2020031
Nov 2020091
Dec 2020040
Jan 2021051
Feb 2021011
Mar 2021062
Apr 2021061
May 2021041
Jun 2021061
Jul 20210100
Aug 20210102
Sep 2021071
Oct 2021042
Nov 2021041
Dec 2021061
Jan 2022060
Feb 2022061
Mar 2022031
Apr 20220114
May 2022080
Jun 2022063
Jul 20220210
Aug 20220244
Sep 2022040
Oct 2022060
Nov 20220113
Dec 20220101
Jan 20230195
Feb 2023080
Mar 2023081
Apr 2023073
May 2023022
Jun 20230162
Jul 20230283
Aug 20230252
Sep 20230121
Oct 2023072
Nov 2023041
Dec 20230442
Jan 20240102
Total043770